Allergan Articles
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
ISTA signs Vitrase deal with Otsuka
7 January 2002
ISTA signs Vitrase deal with Otsuka
20 December 2001
Tsutomu Okimura joins Allergan
22 November 2001
Allergan's Lumigan backed by CPMP
21 November 2001
ExonHit signs first deal in the USA
5 November 2001
FDA approves Allergan's Tazorac cream
18 October 2001
Positive EU opinion for Allergan's Botox
12 October 2001
Allergan to set up R&D center in France
10 September 2001
Allergan selects Business Objectives for BI reporting
5 September 2001
Canadian product news in brief
7 August 2001
Cytochroma expands alliance with Allergan
31 July 2001
US pharma slammed over marketing vs R&D
17 July 2001
ISTA completes Ph III Vitrase trial enrollment
6 July 2001
US seniors' Rx cost rises "are double inflation"
15 June 2001
FDA OK's Berlex' Finevin acne cream
8 May 2001
Allergan exercises option to buy ASTI
19 April 2001
Competition hots up in US glaucoma market
26 March 2001
Allergan legal action against Pharmacia
2 March 2001
Kyorin setting up unit in the USA
2 February 2001
Botox cleared for neck pain in USA
2 January 2001
First approval for Elan's Myobloc in USA - revised
14 December 2000
Allergan returns rBPI rights to Xoma
17 November 2000
Elan's NeuroBloc backed by CPMP
6 November 2000
Allergan's Lumigan "better than timolol"
26 October 2000
Stock Commentary Tokyo
7 September 2000
Allergan licenses Kyorin's gatifloxacin
29 August 2000
Stock Commentary Tokyo
10 August 2000
Stock Commentary New York
6 July 2000
Pharmagene plans London flotation
30 June 2000
Allergan begins two new optical studies
29 June 2000
Stock Commentary New York
23 March 2000
Allergan India to market anti-infectives
2 March 2000
Stock Commentary New York
2 March 2000
Allergan launches Alocril in USA
2 March 2000
BI and Allergan in ocular allergy deal
5 January 2000
Allergan wins FT award
10 November 1999
Allergan appointment
11 October 1999
FDA says Allergan's Restasis is approvable
26 August 1999
Xoma drops amid Neuprex uncertainty
18 August 1999
Stock Commentary New York
29 July 1999
Allergan's Restasis, Phase III data
23 July 1999
Appointment at Allergan KK
15 July 1999
Oxford GlycoSciences appointment
6 May 1999
Allergan's new chief financial officer
29 April 1999
Bioglan deal with Allergan on Zorac
20 April 1999
Bioglan and Allergan form Zorac alliance
16 April 1999
Pharmagene - "Phase Zero" In Drug Development
10 December 1998
Ligand Takes $30 Mill 3rd-Qtr Charge
20 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
$103 Million Restructuring Charge At Allergan
16 September 1998
ALRT Buyback Affects Revenues At Ligand
24 August 1998
Stock Commentary New York
23 July 1998
Allergan 2nd Qtr Sales Increase 14.2%
22 July 1998
Allergan Forecasts Strong 2nd-Qtr Results
9 July 1998
Allergan Appointment
9 July 1998
Laboratoires OM Taking The Global View
14 May 1998
Allergan Licenses CyDex' Captisol Tech
30 April 1998
US Quarterly Financial Results Round-Up
23 April 1998
Management Changes at Allergan
16 April 1998
Merck & Co Tops Patent Table For NCEs
18 March 1998
Resignation At Allergan
5 March 1998
US Corporate 1997 Year-End Results Round-Up
11 February 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Akorn Acquires Paremyd From Allergan
29 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Ligand/Lilly Alliance Gets Underway
27 November 1997
Ligand: Buyout Of ALRT
27 November 1997
9% Rise In Nine-Month Revenues For Ligand
18 November 1997
Market News
30 October 1997
Allergan Pulls Out Of Peptech Collaboration
22 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Appointments And Retirement At Allergan
9 October 1997
Research Collaboration For Allergan and ACADIA
29 September 1997
ALRT Buyout Planned
25 September 1997
Growing Foreign Presence In China's Pharma Industry
22 September 1997
Tazarotene - 1st Effective Topical Retinoid For Psoriasis?
18 September 1997
Ph I/IIa Trial Data With Oral Panretin
4 September 1997
US Corporate Results Round-Up
28 August 1997
Panretin Trial Halted On Positive Results
27 August 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
Allergan To Sell Ophthalmic Facility
7 August 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
FDA Approves Allergan's Tazorac
19 June 1997
ALRT Shares Trading Separately
9 June 1997
Ist Qtr As Expected At Ligand
19 May 1997
Allergan Gains Memantine License From Merz & Co
19 May 1997
Allergan Announces R&D Pipeline Developments
5 May 1997
Launch Expenses Hit Allergan
22 April 1997
Ligand Pharm Moves Ahead In 1996
7 April 1997
Allergan's Alphagan Approved In UK
26 March 1997
Allergan Earnings Down In '97
17 March 1997
Rethink On Asthma Etiology?
17 February 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
